Innovent And Etana Get Indonesian Bevacizumab Nod
Partners Receive Approval For Bevagen Biosimilar To Avastin From Indonesia’s BPOM
Executive Summary
Innovent and marketing partner Etana have celebrated an approval for their Bevagen bevacizumab biosimilar from the Indonesian regulator.
You may also be interested in...
Innovent Expands Internationally With Indonesia Deal
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Innovent’s Adalimumab And Bevacizumab Get New Indications In China
Chinese biotech specialist Innovent Biologics has received approval for new indications for its adalimumab and bevacizumab biosimilars from China’s NMPA.
China Sees Flurry Of Activity On Avastin
An approval for Innovent’s bevacizumab biosimilar has been granted in China, while other potential rivals to Avastin in the region have hit development milestones.